Bacterial News and Research

RSS

Study results from Zolinza (vorinostat) in combination with bortezomib for multiple myeloma trial

Results from two investigational Phase I trials of ZOLINZA (vorinostat) in combination with bortezomib provide preliminary anti-tumor activity in patients with relapsed and/or refractory multiple myeloma.

10 Dec 2007

Pathogens use previously undescribed mechanism to sabotage host immune system

New research identifies a previously unknown enzymatic mechanism that subverts the early host immune response and promotes pathogenicity by manipulating a common signaling pathway in host cells.

10 Dec 2007

Boost for tick disease research

Roman Ganta, a professor of diagnostic medicine and pathobiology at Kansas State University, has been awarded a grant of $1,825,000 by the National Institutes of Health to figure out how to stop the tick-borne bacteria, Ehrlichia chaffeensis, from making animals and people sick.

10 Dec 2007

Purified bacterial extract sprayed into lungs ramps up innate immune system

A purified extract prepared from a common microbe and delivered to the lungs of laboratory mice in a spray set off a healthy immune response and provided powerful protection against all four major classes of pathogens including those responsible for anthrax and bubonic plague, according to a presentation at the American Society for Cell Biology's 47th Annual Meeting.

4 Dec 2007

Humans not the major target of Shiga toxin

If you've survived Shiga toxin and the after-effects of food poisoning, you may have been the innocent victim of a battle for survival between predator and prey.

4 Dec 2007

Molecular technology used to identify unexpected bacteria in cystic fibrosis patients

Molecular technology developed by a University of Colorado at Boulder professor to probe extreme life forms in undersea hydrothermal vents has been used to identify unexpected bacteria strains in the lung fluid of Denver children suffering from cystic fibrosis, findings that may lead to more effective therapies.

4 Dec 2007

Inhaled immune system stimulant launches immune response in lungs to wipe out lethal infections

An inhaled immune system stimulant protects mice against lethal pneumococcal pneumonia and other deadly bacterial, viral and fungal infections of the lungs, a research team led by scientists at The University of Texas M. D. Anderson Cancer Center reports at a major scientific meeting.

4 Dec 2007

Tainted spinach reveals treatment possibilities

A discovery by University at Buffalo biologists that may explain the evolution of a lethal toxin is providing new information that could lead to more effective treatments for humans who fall victim to it.

3 Dec 2007

Benefits of ibuprofen shown to outweigh risks of gastrointestinal bleeding in children with cystic fibrosis

Treatment with ibuprofen is associated with a significantly slower rate of decline in lung function in children and adolescents with cystic fibrosis, according to a new study.

3 Dec 2007

Transporters may help delay diabetes-related retinal damage

Two transporters that deliver alternative energy sources to the eye may help delay retinal damage that can occur in diabetes, researchers say.

29 Nov 2007

Bacteria cheat on their mates for own good

Pursuing our own short term interests by cheating on the rest of the population is not the preserve of the human race.

29 Nov 2007

Uptake of pneumococcal conjugate vaccine among children in the 1998-2002 United States birth cohorts

Since its addition to the list of routine immunizations in 2000, one childhood vaccine has helped prevent some pneumococcal-related illness, including pneumonia and otitis media.

27 Nov 2007

New challenges for diagnosis of bacterial STIs

This year cases of sexually transmitted infections (STIs) have risen by 2% in the UK, in spite of a small drop in the incidence of syphilis and gonorrhoea, according to scientists speaking today (Wednesday 28 November 2007) at the Federation of Infection Societies Conference 2007 at the University of Cardiff, UK, which runs from 28-30 November 2007.

27 Nov 2007

Cholera can be controlled with oral vaccines

Endemic cholera, a potentially fatal diarrheal disease found in the world's most impoverished countries, could be effectively controlled by orally vaccinating half of the affected populations once every two years for only pennies per dose, according to new findings by an international team of researchers led by Ira M. Longini Jr., Ph.D., a biostatistician in the Vaccine and Infectious Disease Institute at Fred Hutchinson Cancer Research Center in Seattle. Longini and colleagues will report their findings online Nov. 27 in PLoS Medicine.

27 Nov 2007

Flip-flopping gene expression can be advantageous

One gene for pea pod color generates green pods while a variant of that gene gives rise to the yellow-pod phenotype, a feature that helped Gregor Mendel, the 19th century Austrian priest and scientist, first describe genetic inheritance.

27 Nov 2007

Chlamydia pneumoniae involved in both heart disease and infertility

Outside the laboratory, Anthony Azenabor is outgoing and talkative, an extrovert who laughs heartily at his own jokes.

21 Nov 2007

Post hurricane skin disorders in clean up workers

Four distinct skin disorders were found in construction workers who helped repair buildings after Hurricane Katrina and Hurricane Rita, according to a report in the November issue of Archives of Dermatology.

20 Nov 2007

Schering-Plough acquires Organon BioSciences

Schering-Plough Corporation has announced that it has completed the acquisition of Organon BioSciences N.V., creating a stronger combined company with broader human and animal health portfolios, an enhanced pipeline and increased R&D capabilities. Schering-Plough's agreement to acquire Organon BioSciences was announced on March 12, 2007.

20 Nov 2007

Cethromycin achieves all endpoints in second pivotal Phase III Trial for treatment for pneumonia

Advanced Life Sciences Holdings, Inc. (Nasdaq: ADLS), today announced positive results from Trial CL-05, the second of two pivotal phase III clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day oral antibiotic for the treatment of mild-to-moderate community acquired pneumonia (CAP), the sixth leading cause of death in the United States.

16 Nov 2007

Discovery of key mechanism in bacterial communication

A team of Princeton scientists has discovered a key mechanism in how bacteria communicate with each other, a pivotal breakthrough that could lead to treatments for cholera and other bacterial diseases.

15 Nov 2007